1. Home
  2. UPBD vs AUPH Comparison

UPBD vs AUPH Comparison

Compare UPBD & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UPBD
  • AUPH
  • Stock Information
  • Founded
  • UPBD 1986
  • AUPH 1993
  • Country
  • UPBD United States
  • AUPH Canada
  • Employees
  • UPBD N/A
  • AUPH N/A
  • Industry
  • UPBD Diversified Commercial Services
  • AUPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • UPBD Consumer Discretionary
  • AUPH Health Care
  • Exchange
  • UPBD Nasdaq
  • AUPH Nasdaq
  • Market Cap
  • UPBD 1.2B
  • AUPH 1.4B
  • IPO Year
  • UPBD 1995
  • AUPH 1999
  • Fundamental
  • Price
  • UPBD $25.23
  • AUPH $12.27
  • Analyst Decision
  • UPBD Buy
  • AUPH Strong Buy
  • Analyst Count
  • UPBD 4
  • AUPH 4
  • Target Price
  • UPBD $34.50
  • AUPH $12.25
  • AVG Volume (30 Days)
  • UPBD 832.1K
  • AUPH 2.8M
  • Earning Date
  • UPBD 07-31-2025
  • AUPH 07-31-2025
  • Dividend Yield
  • UPBD 6.18%
  • AUPH N/A
  • EPS Growth
  • UPBD 78.87
  • AUPH N/A
  • EPS
  • UPBD 1.79
  • AUPH 0.42
  • Revenue
  • UPBD $4,481,986,000.00
  • AUPH $260,111,000.00
  • Revenue This Year
  • UPBD $10.08
  • AUPH $12.15
  • Revenue Next Year
  • UPBD $7.74
  • AUPH $18.34
  • P/E Ratio
  • UPBD $14.09
  • AUPH $29.18
  • Revenue Growth
  • UPBD 7.49
  • AUPH 25.59
  • 52 Week Low
  • UPBD $19.65
  • AUPH $6.42
  • 52 Week High
  • UPBD $36.00
  • AUPH $12.53
  • Technical
  • Relative Strength Index (RSI)
  • UPBD 60.37
  • AUPH 75.72
  • Support Level
  • UPBD $23.58
  • AUPH $11.74
  • Resistance Level
  • UPBD $25.07
  • AUPH $12.53
  • Average True Range (ATR)
  • UPBD 0.73
  • AUPH 0.44
  • MACD
  • UPBD 0.36
  • AUPH -0.00
  • Stochastic Oscillator
  • UPBD 96.94
  • AUPH 80.74

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: